Two monoclonal antibodies, Erbitux® (cetuximab) and Vectibix® (panitumumab), have demonstrated favorable survival impact in population with KRAS wild-type CRC [66, 67]. The gene discussed is KRAS; the disease is colorectal carcinoma.